Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sodium valproate in Huntington's disease.

G R Symington, D P Leonard, P J Shannon

    The American Journal of Psychiatry
    |March 1, 1978
    PubMed
    Summary

    Sodium valproate did not improve involuntary movements in Huntington's disease patients, even at therapeutic plasma levels. Researchers emphasize the need for standardized arousal levels during movement assessments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Prospective study of local cutaneous reactions in patients receiving IV phenytoin.

    Neurology·2001
    Same author

    Epilepsy, depression and antidepressant drugs.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2001
    Same author

    Contemporary management of epilepsy in pregnancy.

    The Australian & New Zealand journal of obstetrics & gynaecology·2001
    Same author

    New antiepileptic drugs.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2000
    Same author

    Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis.

    Clinical and experimental rheumatology·1999
    Same author

    Determination of lamotrigine in human plasma by high-performance liquid chromatography.

    Journal of chromatography. B, Biomedical sciences and applications·1999

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Neurology

    Background:

    • Huntington's disease is a neurodegenerative disorder characterized by involuntary movements.
    • Sodium valproate is known to increase gamma-aminobutyric acid (GABA) levels in the brain.
    • GABAergic dysfunction is implicated in the motor symptoms of Huntington's disease.

    Purpose of the Study:

    • To evaluate the efficacy of sodium valproate in treating involuntary movements associated with Huntington's disease.
    • To investigate the relationship between plasma sodium valproate concentrations and motor symptom improvement.
    • To assess the impact of arousal levels on the measurement of involuntary movements.

    Main Methods:

    • A clinical assessment was performed on three patients diagnosed with Huntington's disease.
    • Sodium valproate was administered, and plasma levels were monitored.
    • Objective ultrasound methods were employed to quantify involuntary movements.
    • Standardized arousal protocols were implemented during assessments.

    Main Results:

    • Sodium valproate administration did not lead to a reduction in involuntary movements.
    • Observed plasma levels of sodium valproate ranged from 47.0 to 140.8 microgram/ml (mean 104.7).
    • No significant correlation was found between plasma drug levels and motor symptom improvement.

    Conclusions:

    • Sodium valproate, despite achieving therapeutic plasma concentrations, showed no benefit in managing chorea in Huntington's disease.
    • The study highlights the critical role of consistent patient arousal in accurately assessing involuntary movement disorders.
    • Further research into GABAergic agents or alternative therapeutic strategies for Huntington's disease is warranted.

    Related Experiment Videos